Editor-in-Chief Emeritus Pick of Papers
Free access for our readers
For each issue of Radiotherapy and Oncology, the Editor-in-Chief Emeritus Jens Overgaard, picks his favourite papers.
- The internal mammary nodes (IMN) receive lymphatic drainage from all quadrants of the breast [1–5], with predominant drainage to IMNs in case of inner quadrant and deeply located nonpalpable tumours . Among patients who have pathologically node-negative axillary disease, up to 10% may have IMN tumour involvement, which increases to almost 40% in case of involved positive axillary nodes [1–6]. IMN dissection was not shown to provide survival benefit . For many years thereafter, elective IMN irradiation was controversial, as data were conflicting for disease outcome benefits vs potential detrimental effects of radiation therapy (RT) [7,8].
- The ACCIRAD project, commissioned by the European Commission (EC) to develop guidelines for risk analysis of accidental and unintended exposures in external beam radiotherapy (EBRT), was completed in the year 2014. In 2015, the “General guidelines on risk management in external beam radiotherapy” were published as EC report Radiation Protection (RP)-181. The present document is the third and final report of the findings from the ACCIRAD project. The main aim of this paper is to describe the key features of the risk management process and to provide general guidelines for radiotherapy departments and national authorities on risk assessment and analysis of adverse error-events and near misses.
- We performed a multi-centre intercomparison of VMAT dose planning and pre-treatment verification. The aims were to analyse the dose plans in terms of dosimetric quality and deliverability, and to validate whether in-house pre-treatment verification results agreed with those of an external audit.
- Online delineation workshops (ODW) permit training of geographically dispersed participants. The purpose is to evaluate the methodology of an ODW using FALCON to harmonize delineation within a European multicentre trial on locally advanced cervical cancer (LACC).